Supercritical solvent impregnation of poly(ɛ-caprolactone)/poly(oxyethylene-b-oxypropylene-b-oxyethylene) and poly(ɛ-caprolactone)/poly(ethylene-vinyl acetate) blends for controlled release applications by Natu, Mădălina V. et al.
Accepted Manuscript
Title: Supercritical Solvent Impregnation of
Poly(-caprolactone/poly(oxyethylene-b-oxypropylene-b-
oxyethylene) and Poly(-caprolactone/poly(ethylene- vinyl
acetate) Blends for Controlled Release Applications
Authors: Ma˘da˘lina V. Natu, M.H. Gil, Hermı´nio C. de Sousa
PII: S0896-8446(08)00189-7
DOI: doi:10.1016/j.supflu.2008.05.006
Reference: SUPFLU 1591
To appear in: J. of Supercritical Fluids
Received date: 8-2-2008
Revised date: 13-5-2008
Accepted date: 29-5-2008
Please cite this article as: M.V. Natu, M.H. Gil, H.C. de Sousa, Supercritical
Solvent Impregnation of Poly(-caprolactone/poly(oxyethylene-b-oxypropylene-b-
oxyethylene) and Poly(-caprolactone/poly(ethylene- vinyl acetate) Blends for
Controlled Release Applications, The Journal of Supercritical Fluids (2007),
doi:10.1016/j.supflu.2008.05.006
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
Page 1 of 40
Ac
ce
pte
d M
an
us
cri
pt
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1
SUPERCRITICAL SOLVENT IMPREGNATION OF POLY(ε-
CAPROLACTONE/POLY(OXYETHYLENE-b-
OXYPROPYLENE-b-OXYETHYLENE) AND POLY(ε-
CAPROLACTONE/ POLY(ETHYLENE- VINYL ACETATE) 
BLENDS FOR CONTROLLED RELEASE APPLICATIONS
Mădălina V. Natu, M. H. Gil, Hermínio C. de Sousa*
CIEPQPF, Department of Chemical Engineering, University of Coimbra, Pólo II-Pinhal de
Marrocos, Rua Sílvio Lima, 3030-790 Coimbra, Portugal
*Corresponding author. Telephone: +351 239 798749. Fax: +351 239 798703. E-mail: hsousa@eq.uc.pt 
(Hermínio C. de Sousa).
Abstract
Poly(ε-caprolactone) blends were successfully impregnated with timolol maleate, an anti-
glaucoma drug, using a Supercritical Solvent Impregnation (SSI) technique. Supercritical 
fluid impregnation efficiency results suggested that the best impregnating conditions were 
obtained when a cosolvent was used and when specific drug-polymer interactions occurred
as a consequence of different chemical structures due to polymer blending. Pressure can be 
either a favourable factor, when there is enough drug affinity for the polymers, or an 
unfavourable factor when weaker bonding is involved. In order to determine the relative 
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hydrophilicity/hydrophobicity of the blends, contact angle analysis was performed, while 
crystallinity determination was also useful to understand the obtained release profiles.
Drug loading, heterogeneous/homogeneous dispersion of drug inside the matrix, 
hydrophilicity, crystallinity, all seem to influence the obtained drug release rates. The “in 
vitro” release results suggested that a sustained drug release rate can be obtained by 
changing the SSI operational conditions and by modulating the composition of blends, as a 
mean to control crystallinity, hydrophilicity and drug affinity for the polymer matrix. After 
a first day burst release, all samples showed a sustained release profile (1.2-4 µg/ml/day,
corresponding to a mass of 3-10 µg/day) which is between the therapeutic and toxic levels
of timolol maleate, during a period of 1 month. These drug-loaded polymeric matrices can 
be a feasible alternative treatment modality for the conventional repeated daily 
administration of eye drops.
Keywords: Supercritical Solvent Impregnation, Poly(ε-caprolactone) blends, Ophthalmic 
drug delivery systems.
1. Introduction
The two main causes of blindness in adult population are age related macular degeneration 
and primary open angle glaucoma, two diseases that affect the posterior segment of the eye
[1]. Glaucoma is frequently asymptomatic at the time of diagnosis, but it can result in 
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3
progressive visual field loss and, in extreme cases, in eventual blindness. Timolol maleate
(a beta blocker) is considered as the “golden standard” against which other glaucoma 
medications are compared in terms of efficacy, side effects and cost. Although topically 
administered timolol maleate is frequently recommended as first-line therapy, some 
systemic side effects of this drug may limit its use. For example, timolol maleate and other 
topically applied beta blockers have been associated to asthma exacerbation, worsening 
congestive heart failure, heart block and, rarely, to sudden death [2].
Low drug bioavailability and systemic toxicity are usually caused by the relative 
impermeability of the cornea, by tear dynamics and blinking and by nasolacrimal drug 
drainage. In the case of eye drops medications, only around 5 % of the applied drug 
actually penetrates through cornea [3]. The drug that is not absorbed by the cornea will
reach the bloodstream through the nasolacrimal duct causing some of the above mentioned 
systemic side effects. To avoid low drug bioavailability, topical eye formulations normally 
require high drug concentrations and frequent dosing treatments which also may increase 
systemic side effects risks.
To overcome these issues, several efforts have been made in order to improve the ocular 
delivery and bioavailability of topically applied ocular drugs and to reduce their adverse 
effects. The most common approach is by developing ophthalmic polymeric-based 
controlled drug delivery systems (CDDSs) such as bioadhesive and in situ forming 
hydrogels, colloidal systems, ocular inserts and implantable devices [4-8].
Polymeric-based CDDSs can be prepared in numerous different ways. Dispersing a drug, or 
therapeutic agent, in biocompatible and/or biodegradable polymeric matrices encompasses 
the majority of all research in this field and there are several well-known methods to 
incorporate and disperse drugs into polymeric matrices. However and in most cases, these 
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4
conventional methods present several disadvantages, like the potential use of toxic organic 
solvents (specially for water insoluble drugs), drug/solvent dissolution and compatibility 
issues, undesired drug reactions, drug photochemical and thermal degradation, low 
incorporation yields and heterogeneous drug dispersion.
Drugs may also be impregnated and dispersed in polymeric matrices by dissolving them in 
compressed high volatile fluids (like carbon dioxide) at temperatures and pressures near or 
above their critical temperatures and pressures, and contacting the resulting mixture with 
the polymeric matrices to be infused. In these conditions, the compressed fluid can act also 
as a swelling and plasticizer agent for polymers, dilating the matrices and helping drug 
diffusion into them. This recent technique, known as Supercritical Solvent Impregnation 
(SSI), already proved its advantages for the development of drug impregnated polymeric 
materials which can be used as CDDSs for many biomedical applications [9-12]. SSI 
allows the drug impregnation of most polymeric articles and, when properly employed, 
without altering and/or damaging their physical, chemical, and mechanical properties and 
without degrading their constituent drugs, additives and polymers. Furthermore, drug 
loading and depth penetration can be easily controlled and drugs will be homogeneously 
dispersed, in short treatment times and leaving no harmful solvent residues. Finally, SSI 
also permits to have previously prepared polymeric articles and, later, impregnate them 
with the desired drugs, according to the specific needs of the envisaged therapeutic 
application, and without interfering with the established conventional method/procedure to 
produce/process the original polymeric articles. This particular feature can lead to very 
attractive and useful medical and commercial applications [13-14].
Although carbon dioxide is the most frequently employed supercritical fluid (SCF), it also 
presents several limitations mainly due to its inability to dissolve high molecular weight 
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compounds and to its non-polarity and lack of several specific solvent-solute and solvent-
polymer interactions that would lead to high polymeric drug loading.
A frequent strategy to increase drug solubility in supercritical carbon dioxide (scCO2) is the 
addition of small amounts of specific cosolvents which can produce dramatic effects on its 
solvent power, sometimes up to several hundred percent in terms of solubility enhancement 
[15-16].
Our long-term goal is to prepare an implantable (subconjunctival) system for continuing
drug delivery, with controlled release and degradation that could deliver timolol maleate 
for up to 4-6 months, in an attempt to overcome the problems of low drug bioavailability 
and the potential occurrence of systemic toxicity. The system would deliver only the 
therapeutic drug amount [17] and would eliminate the problem of frequent administration 
(timolol eye drops are applied twice daily), improving patient compliance.
For the present study, poly(ε-caprolactone) (PCL) was selected as the main blend 
homopolymer for the preparation of the biodegradable CDDS due to its good 
biocompatibility [18-20] and its known swelling ability in scCO2 [21]. Poly(ethylene-co-
vinyl acetate) and poly(oxyethylene-b-oxypropylene-b-oxyethylene) are block copolymers 
which have numerous and recognised applications in the development of CDDSs mainly 
because of their biocompatibility, processability (e.g. extrusion) and proved long-term 
release properties [22-26].
The aim of this work was to evaluate the effects of operational pressure, of blend chemical 
nature and composition, as well as of cosolvent effects, on the supercritical solvent 
impregnation process of different poly(ε-caprolactone) blends, in order to determine the 
best operating conditions to achieve maximum drug loading and optimal drug release 
profiles.
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2. Experimental section
2.1. Materials
Timolol maleate, (99,6 % purity) was purchased from Cambrex Profarmaco Cork Ltd., 
Ireland. Poly(ε-caprolactone) pellets (PCL, average Mw 65000 g/mol) were obtained from 
Sigma-Aldrich. Poly(ethylene-co-vinyl acetate), Luwax EVA 3 (Lw, 13-15 % vinylacetate 
content) and poly(oxyethylene-b-oxypropylene-b-oxyethylene), Lutrol F 127 (Lu, 9000-
14000 g/mol, 70 % by weight of polyoxyethylene) were bought from BASF. It was not 
possible to obtain (from supplier) the average molecular weight of Luwax EVA 3. The 
chemical formulae of the employed copolymers are shown in Fig. 1. Tetrahydrofurane 
(HPLC grade) was obtained from Sigma-Aldrich. Phosphate buffer saline (PBS) tablets 
(pH 7.4, 10 mM phosphate, 137 mM sodium, 2.7 mM potassium) were used to prepare the 
drug release medium and were bought from Sigma-Aldrich. Carbon dioxide (99.998 % 
purity) was obtained from Praxair. All products were used without further purification.
2.2. Blends preparation
Several PCL-based blends were prepared by solvent casting and according to the procedure 
described below. The blends (Lutrol F 127/PCL: 25/75, 50/50 and Luwax EVA 3/PCL: 
25/75, 50/50, 75/25, % w/w) were prepared by dissolution in tetrahydrofuran (10 % w/v 
total polymer solutions) at 40 °C and 60 °C, respectively. Blends films were obtained by 
solvent casting at room temperature in glass Petri dishes. Then, the obtained films were 
vacuum-dried at 37 °C, for 24 h, to ensure the complete removal of the solvent. After 
drying, the films were removed from the Petri dishes and cut in rectangular pieces of 
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7
approximately 0.5 cm×0.5 cm and used as such in the subsequent supercritical 
impregnation of the drug and characterization experiments.
2.3. Supercritical fluid impregnation process
The supercritical solvent impregnation equipment is schematically presented in Fig. 2. The 
equipment consists of a cylindrical high-pressure stainless steel cell (21.57 cm3) placed in a 
controlled temperature water bath that maintains the temperature within ±1 °C. The water 
bath temperature was measured by means of a digital thermometer. A magnetic stirring 
plate (750-800 rpm) was used to homogenise cell-containing high pressure mixtures (CO2, 
timolol maleate and cosolvent). Carbon dioxide was liquefied through a cooling unit and 
compressed to the operating pressure with a high-pressure liquid pump. A one-way high 
pressure valve (3) was introduced in the system. System pressure was measured with a 
pressure transducer in-line with the impregnation cell.
The drug, or drug solution (in the cases when cosolvents were used), was loaded in the 
bottom of the cell and the polymer films (with masses between 0.01-0.02 g) were separated 
in a stainless steel grid, placed in the centre of the cell. The amount of drug was established 
in order to obtain a saturated environment at the operational conditions. A cosolvent 
concentration of 10 % (v/v), at PTN conditions, was used in order to increase drug 
solubility in scCO2 [27]. Then, carbon dioxide was allowed to flow through the cell to 
remove all the air from the system. Then, valves 11 and 12 were closed and the cell was 
loaded with CO2 until the desired pressure and temperature conditions were attained. After 
this, valve 6 was closed and the system was maintained static and under constant pressure 
during the two hours of impregnation experiments.
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At the end of the impregnation period, the system was depressurized (depressurization rate 
was 5 bar/min) in order not to alter or damage the polymeric samples. For this, two 
consecutive valves (11 and 12) were used in order to have a greater control over the 
depressurization rate. Impregnated samples were then recovered in a dry or soaked state 
(when cosolvent was used). Wet samples were dried in a vacuum oven at 37 °C for 2 
hours. Then, sample masses were registered in order to calculate the impregnation 
efficiency (Section 2.4).
A pressure of 200 bar and a temperature of 40 °C were chosen because scCO2 has the 
highest solubility (3.2 g/g of PCL) in poly(ε-caprolactone) at these operational conditions 
[21]. At these conditions, PCL presents a maximum swelling degree which, supposedly, 
may help diffusion and increase drug loading yields. A second operational pressure (110 
bar) was chosen in order to study the possible pressure effects on the resulting polymer 
blends on which we didn’t have any previous data regarding the solubility of scCO2 in 
these polymeric matrices. The operational parameters for each of the performed 
experiments are summarised in Table 1.
2.4. Impregnation efficiency
The impregnated timolol maleate mass (md) was determined spectrophotometrically by 
UV-vis analysis (Jasco V-530 Spectrophotometer), at 299.5 nm, after dissolving the
impregnated blends in tetrahydrofuran. The impregnation yield was calculated using Eq. 1. 
Triplicate assays were performed in order to obtain the experimental standard deviation.
Impregnation efficiency (g drug/g blend) d
p
m
m
 (1)
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9
In this equation, mp is the polymer mass after the impregnation process. For each different 
blend composition, the operating conditions leading to the highest impregnation were 
selected and only these impregnated samples were tested for the in vitro kinetics drug 
release experiments.
2.5. Contact angle measurements
The contact angle formed between a water droplet placed on the surface of a material and 
the kinetics of spreading is related to the hydrophilicity/hydrophobicity of the material.
Water contact angles of the prepared polymer blend films were evaluated by static contact-
angle measurements using an OCA 20 from Dataphysics. The tests were performed on the 
air-facing surfaces of the samples, using water and employing the sessile drop method. 
Nine measurements on different sample points were performed to calculate the mean static 
contact angle and its standard deviation.
2.6. DSC - Crystallinity determination
Differential scanning calorimetry (DSC) was carried out using a SDT Q 600 calorimeter, 
from TA Instruments. Films were heated under a constant nitrogen gas flow at a heating 
rate of 10 °C/min. DSC results were calibrated using indium as the calibration standard. 
The melting temperature of the blends was considered as the temperature at which the 
endothermic peak occurred. The fusion enthalpy, for each blend, was determined 
integrating the peaks from the melting endotherm using the TA Analysis software. The 
relative crystallinity, Xrel of the blends was calculated using Eq. 2 [28-29]:
100(%)
%100,



f
f
rel H
H
X (2)
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10
In Eq. 2, ΔHf is the experimental fusion enthalpy of the blends. The value of ΔHf,100% was 
used considering the reported fusion enthalpy of 100 % crystalline polycaprolactone [30].
2.7. In vitro kinetics of drug release studies
The kinetics of timolol maleate release from the prepared materials was studied in PBS 
medium at 37 °C. The impregnated blend samples were compressed in a mould, using a 
press, into discs of 6 mm diameter and 1 mm thickness. These discs were weighed and 
introduced in vials containing 4 ml of PBS and maintained at 37 °C. At scheduled time 
intervals (every 15 minutes during the first hour, then every hour during 6 hours, twice a 
day during 2 days and finally once a day for the remaining time), half of the the PBS/drug 
solution was removed from the vial and a fresh PBS solution of identical volume was 
added to maintain sink conditions. The timolol maleate concentration in each of the 
collected samples was measured at 299.5 nm using a Jasco V-530 Spectrophotometer. The 
amount of timolol maleate released at time t (mt), was determined from a pre-determined 
standard curve (with an absorption co fficient ε299.5 = 20.97±1.51 ml/mg cm). The total 
amount (mtotal) of impregnated timolol maleate was determined after the release test ended, 
by dissolving the blends in tetrahydrofuran and adding this residual mass to the
accumulated released mass. The percentage of released drug was calculated using Eq. 3. 
Calculations of the amount of released drug took into account the drug removal and the 
replacement with fresh medium at each sampling point.
Released drug (%) 100t
total
m
m
  (3)
In order to study the drug release mechanism, the Korsmeyer-Peppas equation (Eq. 4) was 
used [31]:
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n
total
t tk
m
m  (4)
In this equation, mt/mtotal is the fractional release of the drug, k is the kinetic constant and n
is the release exponent, which gives an indication of drug release type of mechanism. 
Following the Korsmeyer-Peppas equation, only the experimental drug release data tha  
satisfied the relation mt/mtotal ≤0.6 were employed for the determination of the release 
exponent. Release exponents, n, were calculated as the slopes of the straight lines fitted to 
the release data using a least squares method.
3. Results and discussion
3.1. Contact angle measurements
Contact angles are characteristic constants of liquid-solid systems and, when water or 
aqueous solutions are used as the liquids, may provide valuable information on the solid 
surface hydrophilicity or hydrophobicity. This information is of great importance for the 
development of polymeric CDDSs since water-promoted polymeric swelling will strongly 
influence drug diffusion through the polymeric network as well as polymeric 
erosion/dissolution and degradation [32]. The obtained water-polymeric blends contact 
angles are presented in Table 2. These results show that all the prepared blends, as well as 
the individual polymers and copolymers, are mainly hydrophilic (contact angles < 90º). 
But, and for the investigated individual samples, we can assume that Lu is the more 
hydrophilic sample, PCL has an intermediate hydrophilic character and Lw is the less 
hydrophilic sample. Moreover, and as expected, obtained blend contact angles are 
intermediate values of the constitutive polymers and copolymers. Thus, as PCL content is 
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increased in Lu/PCL blends, the resulting blend samples become less hydrophilic. The 
same behaviour is observed when Lw content is increased in Lw/PCL blends: contact angle 
increased because the overall hydrophobic content of the blend was also increased. These 
results were confirmed by water swelling experiments, which will be reported in due time, 
together with other blend characterization data. Due to the specific interactions that may 
occur between polymers/copolymers, resulting blends and the involved solvents, these 
different relative hydrophobicity/hydrophilicity characters may have a strong influence on 
the obtained kinetics of drug release results and on the impregnation efficiency results, as it 
will be discussed later.
3.2. DSC - Crystallinity determination
Polymer and copolymer crystallinity is known to play an important role in determining 
degradability, erosion, water and drug permeability because the bulk crystalline phases that 
may be present become more inaccessible to water diffusion. Moreover, scCO2 induced 
crystallization of polymeric substrates can also influence the overall supercritical solvent 
impregnation process as well as the final relative crystallinity of the processed polymeric 
materials [9, 12, 33-36].
PCL, Lu and Lw are semi-crystalline polymers and copolymers and, in their blends, the 
overall final crystallinity degree may be strongly influenced by blend composition, by the 
relative crystallinity of each component in the blend and by the specific interactions that 
may occur between blend components or between specific blocks of the involved 
copolymers in the blend. As shown in Table 3, the relative crystallinity, Xrel (%), calculated 
using Eq. 2, increases with the PCL ratio in Lw/PCL blends and decreases with the PCL 
ratio in Lu/PCL blends.
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We did not find any previously reported values for the fusion enthalpy of 100% crystalline 
Lu and Lw, ΔHf,100%, and thus it was not possible to calculate the relative crystallinities for 
these pure copolymers. However, the measured fusion enthalpies for both pure Lu and Lw 
are higher than the corresponding value for PCL. Usually this is an indication that their 
relative crystallinity values should also be higher than the corresponding value for PCL.
Therefore, it should be expected that blends with higher Lu and Lw contents should also 
present higher relative crystallinities. This happens for Lu/PCL blends and this behaviour 
was already found and discussed in other works involving, for example, polyethylene 
oxide/PCL blends [37].
Despite this rule, some exceptions may occur especially when the co-crystallization of 
blend components can take place with some crystallization restrictions of one component 
due to the presence of the second one. For example, in the case of Lw/PCL blends, as the 
proportion of Lw in the blend is increased, the expected higher crystallization ability of Lw 
can be restricted and, as a consequence, the final relative crystallinity decreases.
Furthermore, and again in the case of Lw/PCL blends, it has been proposed that the 
carbonyl groups from polyesters can interact favourably with the α-hydrogens of the 
poly(vinylacetate) (PVAc) block due to their proton accepting and proton donating 
properties, respectively. Such favourable interactions between PCL and the PVAc block 
can be responsible for the commonly found miscibility of PCL/PVAc blends [38]. It is also 
accepted that the favourable interactions that are often established between two 
constituents in miscible blends can contribute to slowing down of the formation rate of
crystallising species being drawn into (or diffusing to) the crystals [39]. Therefore, these 
are other possible explanations of why, in the Lw/PCL series, the addition of Lw causes a 
decrease in relative crystallinity in comparison with pure PCL. The obtained fusion 
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enthalpies of these blends are also smaller than that obtained for PCL alone, further 
sustaining these hypotheses.
3.3. Supercritical drug impregnation process
The 75/25 Lu/PCL blend was not studied because it was found that it dissolves in PBS, at 
37 °C, and thus it is not a good material for the intended CDDS application. The 25/75 
Lu/PCL, 50/50 Lu/PCL blends, as well as PCL samples, were not impregnated using 10% 
of ethanol as cosolvent because the samples would dissolve completely at these operational 
conditions.
It is important to notice that the employed cosolvent compositions are expressed in terms 
of volume fractions (v/v) and are referred to PTN conditions. In the case of ethanol, at the 
experimental conditions (40 ºC/110 bar and 40 ºC/200 bar), these compositions are slightly 
different from this value but all ethanol was dissolved and the experiments were performed 
employing a homogeneous supercritical fluid phase mixture (CO2+ethanol). However, in 
the case of water, and because an excess of cosolvent was added to the cell, there are 
always two immiscible phases inside the cell, with compositions determined by the high 
pressure vapour-liquid equilibria of CO2+water mixtures, at those pressure and temperature 
conditions: a high pressure fluid mixture (CO2+water), in contact with the polymeric 
samples, and a high pressure liquid phase (water+CO2), at the bottom of the cell.
In general terms, the obtained results indicate that not just timolol maleate solubility 
(which is highly dependent on the presence or absence of the cosolvent) in scCO2 plays an 
important role in the overall impregnation process efficiency, but also all the other specific 
and complex interactions that may occur between all the involved components of the 
system: scCO2-polymeric matrices-cosolvent interactions (which determine cosolvent and 
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scCO2 solubility in the polymeric matrix and, consequently, swelling and plasticization 
effects) and drug-polymeric matrices-cosolvent interactions (which control the 
entrapment/deposition of the drug in the polymeric network).
In Fig. 3, a) and b), the effect of cosolvent on impregnation efficiency is illustrated for both 
employed impregnation pressures. It is clear that, for the Lw/PCL blends, the highest 
impregnation yields (0,018-0,033 g/g) were obtained when using ethanol (at both 
operational pressures) while for Lu/PCL blends, highest impregnation yields (0,012-0,018 
g/g) occurred in the presence of water as cosolvent (also at both employed pressures). For 
pure PCL samples, best results (0,009 g/g) were achieved when no cosolvent was used and, 
as observed, water addition decreased the amount of impregnated drug. As already referred, 
ethanol was not employed with pure PCL.
Therefore, the presence of the cosolvent and its inherent nature radically changed the 
impregnation results for these blends: ethanol visibly promoted Lw/PCL blends 
impregnation while water promoted Lu/PCL blends impregnation.
These results can be explained by the favourable specific interactions drug-CO2-cosolvent
that may occur, i.e., by the timolol maleate (a water-soluble polar drug) solubility
enhancement in the high pressure fluid phase, which was caused by the polarity increase of 
the mobile phase when the polar cosolvents (ethanol and water) were added [40]. As more 
drug can be dissolved, more drug can be carried out into the polymeric network by the 
mobile high pressure phase. In the case of timolol maleate, this ethanol induced solubility 
enhancement was already measured in our group [27].
For water, and to the best of our knowledge, there isn’t any high pressure timolol maleate-
CO2-water solubility data in the literature. However, and because timolol is a water soluble 
molecule and water is much more polar than ethanol, we should expect the same (or even 
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higher) solubility enhancement as the one observed for ethanol. However, when water was 
employed as cosolvent, the impregnation efficiencies increased for Lu/PCL blends but for 
Lw/PCL blends were drastically reduced. This suggests that other different phenomena 
should also be involved in the impregnation process. A possible explanation can be the 
occurrence of favourable specific timolol-maleate-polymeric matrix-ethanol interactions
for Lw/PCL blends and of specific timolol-maleate-polymeric matrix-water interactions for 
Lu/PCL blends. Ethanol/blends contact angle measurements were not performed but 
water/blends contact angle experiments indicated that Lu/PCL blends were more 
hydrophilic than pure PCL and than Lw/PCL blends. Therefore, a high pressure mobile 
phase containing water may interact more efficiently with Lu/PCL blends than with pure 
PCL and with Lw/PCL blends, thus promoting a higher swelling degree and consequently 
favouring diffusion. This effect seems to be increased at higher pressures (200 bar). 
Furthermore, and if there is some water absorption in the hydrophilic portions of Lu/PCL
blends (as expected), this will also create the conditions for a water-soluble molecule, like 
timolol maleate, to be deposited in these blends, instead of being removed with the mobile 
phase during depressurization.
A recognized advantage of SCF polymeric processing is that SCFs can enhance the 
diffusion of drugs+SCFs mixtures into some polymeric matrices because, in most cases, 
they can increase the polymeric free volume and the side groups chain mobility. 
Furthermore, this diffusion enhancement can be controlled (“tuned”) just by changing the 
operational pressure and temperature. When polymer-SCF phase interactions are present
and are favourable, high pressures usually facilitate the diffusion process mostly because 
they will allow more fluid absorption which will generate a higher swelling degree. This is 
the case when higher operational pressure determines higher drug loading in the polymeric 
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matrix. On the other hand, when drug-SCF phase interactions are stronger than drug-
polymer interactions, pressure usually will be an unfavourable factor because higher 
pressures will originate an increase in SCF phase density, thus leading to an increased 
solvating power of the mobile phase. At the same time, and if the polymer-SCF phase 
interactions are still appreciable, this increased density will also originate an increase in 
polymer swelling. As a result of these two combined factors, more drug will “choose” to 
diffuse out the polymeric matrix and stay in the mobile phase, originating a low polymeric 
loading [41].
In Fig 4 a), b) and c), we present the explicit effect of pressure on the impregnation 
efficiencies. Pressure effects complement the previous discussion about the cosolvent 
effects on impregnation efficiencies and can also help to explain why impregnation 
efficiencies are higher at 200 bar for Lu/PCL blends, while Lw/PCL blends and PCL have 
higher impregnation efficiencies at 110 bar. More effective drug-polymer interactions are
expected to take place for Lu/PCL blends because of Lu/PCL blends higher 
hydrophilicities. Thus, higher pressures will favour drug deposition. For Lw/PCL blends 
and for PCL samples, drug diffusion into the polymeric samples also takes place but, 
during depressurization, more drug comes out with the mobile phase, due to the weaker 
drug-polymer interactions (when compared to the drug-SCF phase interactions). This is 
also in agreement with other works in which the efficiency of the impregnation decreases at 
higher pressures [42].
As already referred, copolymer/polymer chemical structures can strongly affect drug-
polymer and polymer-SCF phase interactions, thus controlling the overall impregnation 
process. These complex interactions can be understood, for example, through the 
supercritical surfactants theory. Generally, surfactants for use with carbon dioxide are 
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amphiphilic molecules containing both a CO2-phobic and a CO2-philic portion [43]. For 
Lutrol F 127 (which is a non-ionic surfactant), the ethylene oxide segment is the 
hydrophilic portion of the block copolymer but it also is less CO2-philic than the 
polypropylene oxide segment. However, it still interacts with CO2 thus still having some 
swelling degree in scCO2 media. The polypropylene oxide segment has superior CO2-
philicity (when compared to the polyethylene oxide block) mainly because of the pending
methyl groups along its backbone). Luwax is a copolymer containing a hydrophobic part 
(polyethylene) and a slightly hydrophilic one (polyvinylacetate). In terms of CO2
interactions, we can assume than the polyethylene block will interact in a stronger way with 
CO2 than the polyvinylacetate block, thus being more CO2-philic than the PVAc segment.
Finally, PCL is a homopolymer that is known to interact strongly with CO2 [21]. This 
happens because of the methylene groups present on its backbone as well of the specific 
interactions that can occur between CO2 and carbonyl groups.
Therefore, a hydrophilic drug (like timolol maleate) when is transported by a SCF, or by a 
SCF-cosolvent mixture, will have a tendency to specifically interact and deposit on the 
hydrophilic portions of the employed polymeric matrices. However, and because CO2 is 
also interacting in a strong way with the hydrophobic (CO2-philic) portions of the 
polymeric matrix, a hydrophilic drug can also be deposited (in a lower extent) in these 
hydrophobic portions. The use of a hydrophilic cosolvent (like water and ethanol, as 
already discussed), will yet increase these interactions with the more hydrophilic parts of 
the polymeric matrices thus increasing impregnation efficiency. If a hydrophobic drug is 
used, we should expect that these effects will influence impregnation efficiency in an
opposite way.
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Consequently, we should expect that more timolol maleate would be impregnated in 
Lu/PCL blends as the composition, in terms of the more hydrophilic blend compound (Lu), 
is increased. In Fig. 5 a), this is verified but only when water is used as the cosolvent. For 
Lw/PCL blends, Fig. 5 b), the same effect is observed and as the Lw content is increased
(the more hydrophobic component), the impregnation efficiency decreases, but only in the 
case when ethanol is employed. In the case of Lw/PCL blends, and as already discussed in 
terms of water-samples contact angles and relative hydrophilicity, water seems to not affect 
greatly the impregnation efficiency.
Finally and as already mentioned, the scCO2 induced crystallization of some polymeric 
substrates can occur during the impregnation experiments, decreasing the overall chain
mobility of the involved polymeric materials. This effect is contrary to the favourable 
plasticization effect and can increase the final relative crystallinity of the processed 
polymeric materials, thus influencing negatively the overall impregnation efficiency [9, 12, 
33-36]. However, we did not measure the relative crystallinity of the employed materials 
after scCO2 and scCO2+cosolvent processing and therefore we did not know if crystallinity 
increased or decreased. This work is still being performed and results will be presented in 
due time.
3.4. In vitro kinetics of drug release studies
In vitro kinetics of drug release studies were performed for selected impregnated samples. 
This selection was made taking in consideration the best impregnation conditions, in terms 
of impregnation efficiency, for each set of blends or sample: 200 bar/ 10 % water for 
Lu/PCL blends, 110 bar/ 10 % ethanol for Lw/PCL blends and 110 bar/ 0 % cosolvent for 
PCL samples. Results are presented in Fig. 6 a) and b). The cumulative percentages of 
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released timolol maleate are shown in Fig. 6 a). A magnification of the initial 8 hour 
release period is also shown. After 32 days of release studies, the cumulative released 
percentages were found to be higher for the Lw/PCL blends, followed by the Lu/PCL 
blends and, finally, by PCL (84.6-92.3 %, 79.2-79.9 % and 77.2 %, respectively). All the 
impregnated samples presented almost the same drug release profile, i.e., a biphasic release 
pattern: an initial burst period exhibiting a very rapid release rate (probably caused by the 
drug deposited on/near the polymeric surface), followed by a polymeric swelling and/or 
erosion period, exhibiting an almost constant release rate (3-10 μg/day after the first day). 
We must remember that Lutrol F 127 is soluble in water and poly(ε-caprolactone)
undergoes hydrolytic degradation.
The obtained results seem to indicate that the initial drug loading of the supercritical 
impregnated samples somehow influenced drug release kinetics results: the higher
cumulative percentages of released drug were obtained for the samples which were 
impregnated with higher drug amounts (Lw/PCL blends impregnated with 10% ethanol).
However this could not be the true reason for these observations and a possible explanation 
may be that timolol maleate was released faster in Lw/PCL blends because most part of 
impregnated drug was probably deposited very close to the surface. This will be confirmed 
further on when the kinetics modelling results will be discussed.
Lu/PCL blends and PCL were impregnated in a lesser extent but show more sustained drug
release profiles. These results are probably due to the fact that these lower impregnated 
amounts of drug (when compared to Lw/PCL blends) were deposited more deeply in the 
polymeric structure (thus more homogeneously dispersed throughout all the polymeric 
samples). And, this was the result of the favourable specific interactions that were 
established between timolol maleate, water (cosolvent) and the highly hydrophilic 
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segments of the Lu/PCL blends (as discussed in section 3.3.). In addition, sample 
crystallinity may also control the drug release rates (higher crystallinity degrees usually 
lead to slower release rates) and Lu/PCL blends and PCL present the highest percentage of 
crystalline phases (see Table 3).
Cumulative released drug concentration results are presented in Fig. 6 b). It can be seen 
that, after the initial first day burst release, timolol maleate concentration becomes almost 
constant (1.2-4 μg/ml/day corresponding to a mass of 3-10 μg/day), which is located above 
the therapeutic limit of timolol maleate (5 μg/day) [44] and below the maximum 
recommended human ophthalmic dose (0,42 mg/day, considering a patient weight of 60 
kg) [45]. The burst dose, released by the systems during the first day is below the 
maximum recommended human ophthalmic dose, with two formultions surpassing this 
value (0.53 mg for 50/50 Lw/PCL and 0.78 mg for 75/25 Lw/PCL). Even these values are 
well below the maximum recommended daily oral dose, which is 60 mg/day (considering a 
patient weight of 60 kg) [46]. The knowledge of these values is essential for the 
development of efficient and safe controlled drug release systems because the released drug 
concentrations must always be kept between the therapeutic and toxic levels.
The Korsmeyer-Peppas model (Eq. 4) is usually employed to analyse kinetics of drug 
release from systems where the release mechanism is not well-known or when more than 
one type of release phenomena (diffusion-, swelling- or erosion-controlled) are involved. 
For cylindrical systems, release profiles having a release exponent, n, around 0.45, exhibit
a drug release mechanism controlled by classical/Fickian diffusion. When n~0.89, the drug 
release rate is controlled by a polymer relaxation mechanism (or Case II transport). 
Systems having release exponents, n<0.45, account for pseudo-Fickian behaviour, while 
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when 0.54<n<0.89 are an indication of the superposition of both the above referred 
phenomena. In this case, the release mechanism is termed anomalous transport [46-47].
The value of the release exponent, n, was calculated as the slope of the straight lines fitted 
to the release data using the least squares method (Fig. 7). The obtained values are 
presented in Table 4 and, for all systems, n<0.45, accounting for pseudo-Fickian release 
behaviour. Steeper slopes were obtained for Lw/PCL blends which confirmed the already 
discussed higher initial burst release behaviour observed for these systems. As expected, 
and in general terms, results suggest that the release mechanism is quite complex, as drug 
diffusion, polymeric swelling, crystallinity and polymer erosion are all likely to contribute 
to the overall release phenomenon.
4. Conclusions
Lu/PCL, Lw/PCL blends and PCL samples were successfully impregnated with timolol 
maleate, an anti-glaucoma drug, in order to, as a final objective, prepare polymeric 
implantable (subconjunctival) systems for long-term timolol delivery, with controlled 
release and degradation .
Different blends (with distinct blend components and compositions) were prepared and 
characterized in terms of water-sample contact angle measurements and sample relative 
crystallinity. Several SSI experimental conditions were tested: blend composition, 
impregnation pressure and different cosolvents (water and ethanol).
Impregnation efficiency was determined and the obtained showed indicated that, and in 
general terms, the overall impregnation process and its efficiency is the result of the 
relative specific interactions that may be established between all the involved components 
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of this complex system: scCO2-cosolvent-drug interactions (which control drug solubility 
in the high pressure mobile phase and its overall polar character), scCO2-polymeric 
matrices-cosolvent interactions (which determine cosolvent and scCO2 solubility in the 
polymeric matrix and, consequently, swelling and plasticization effects) and drug-
polymeric matrices-cosolvent interactions (which control the entrapment/deposition of the 
drug in the polymeric network). In addition, the employed polymeric samples, with the 
exception of PCL, are copolymer blends and each one of these copolymers has 
blocks/segments with different hydrophobic/hydrophilic characters, thus increasing even 
more the system complexity.
However, in specific impregnation conditions, the addition of a cosolvent (water and 
ethanol for Lu/PCL and Lw/PCL, respectively) promotes higher drug loading. This 
happened because, in these conditions, drug solubility is increased and higher drug 
amounts can be transported by the mobile phase. Moreover, the relative 
hydrophilicity/hydrophobicity of prepared blends, together with the cosolvent addition, also 
seemed to affect favourably the impregnation process (because of the specific favourable 
interactions that are formed between the drug, cosolvent and the more hydrophilic blend 
segments). Higher pressures were either a favourable factor (for Lu/PCL blends) or an
unfavourable factor (for Lw/PCL blends and for PCL samples).
Selected impregnated samples (the ones that presented higher impregnation efficiencies) 
were employed in kinetics of drug release studies and the obtained results indicated that the 
higher cumulative percentages of released drug were obtained for the samples which were 
impregnated with higher drug amounts (Lw/PCL blends impregnated with 10% ethanol). 
However, these systems presented high initial drug burst release profiles. Lu/PCL blends 
and PCL were impregnated in a lesser extent but they showed more sustained/controlled
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drug release profiles. These results are probably due to the fact that timolol maleate was 
more homogeneously dispersed throughout all the polymeric samples, as the result of the 
favourable specific interactions that were established between timolol maleate, water 
(cosolvent) and the highly hydrophilic segments of Lu/PCL blends. In addition, and for 
these blends, sample crystallinity may have also influenced drug release rates because of
the Lu/PCL blends and PCL higher percentages of crystalline phases. These results were 
confirmed by the application of Korsmeyer-Peppas model, that accounted for pseudo-
Fickian release behaviour for all the tested samples, which indicates that the release 
mechanism is quite complex, as drug diffusion, polymeric swelling, crystallinity and 
polymer erosion are all expected to contribute to the global release phenomenon.
After the first release day, all samples showed a sustained release of 1.2-4 g/ml/day,
corresponding to a mass of 3-10 g/day, during a period of 1 month. These values are 
between the therapeutic and toxic levels of timolol maleate.
The obtained impregnation efficiencies and drug release results suggested that a desired 
final sustained drug release rate can be achieved by changing several operational 
impregnation conditions and by modulating blend compositions, i.e., as a way to control 
crystallinity, hydrophilicity and drug affinity for the polymer matrix. 
As final conclusions, the prepared timolol maleate-loaded polymeric matrices can be a 
feasible and promising alternative to the conventional repeated daily administration of 
timolol maleate eye drops for glaucoma treatment. Moreover, the SSI method proved to be 
a good choice and a “tunable” method for the preparation of these long-term controlled 
release systems.
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CAPTIONS TO FIGURES
Fig 1. Chemical structures of the employed polymers and copolymers.
Fig 2. Schematic diagram of the experimental supercritical solvent impregnation 
apparatus: (1) CO2 reservoir; (2) High-pressure CO2 pump; (3) One-way valve; (4, 5, 6, 
11, 12) Valves; (7) Water bath heater/controller; (8) High-pressure stainless steel 
impregnation cell; (9) Digital thermometer; (10) Pressure transducer; (13) Glass trap.
Fig 3. Cosolvent (water and ethanol) effects on impregnated samples. a) 110 bar; b) 200 
bar, (●) 50/50 Lu/PCL, (○) 25/75 Lu/PCL, (▼) PCL, () 25/75 Lw/PCL, (■) 50/50 
Lw/PCL, (□) 75/25 Lw/PCL.
Fig 4. Pressure effect on impregnated samples. a) No cosolvent; b) 10% water; c) 10% 
ethanol. (●) 50/50 Lu/PCL, (○) 25/75 Lu/PCL, (▼) PCL, () 25/75 Lw/PCL, (■) 50/50 
Lw/PCL, (□) 75/25 Lw/PCL.
Fig 5. Effects of blends compositions. a) Lu/PCL blends; b) Lw/PCL blends. (●) 0 % 
cosolvent, 200 bar, (○) 10 % water, 200 bar, (▼) 10 % ethanol, 200 bar, () 0 % 
cosolvent, 110 bar, (■) 10 % water, 110 bar, (□) 10 % ethanol, 110 bar.
Fig 6. Kinetics of drug release studies. a) Cumulative percentages of released timolol 
maleate; b) Cumulative concentrations of released timolol maleate. (●) 50/50 Lu/PCL
(200 bar, 10% water), (○) 25/75 Lu/PCL, (200 bar, 10% water), (▼) PCL, (110 bar, 0%
cosolvent), () 25/75 Lw/PCL, (110 bar, 10% ethanol), (■) 50/50 Lw/PCL, (110 bar, 
10% ethanol), (□) 75/25 Lw/PCL, (110 bar, 10% ethanol).
Fig 7. Linear regressions to calculate kinetic constants and release exponents. (●) 50/50 
Lu/PCL, (○) 25/75 Lu/PCL, (▼) PCL, () 25/75 Lw/PCL, (■) 50/50 Lw/PCL, (□) 
75/25 Lw/PCL.

Figure(s)
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Table 1. Employed impregnation experiments operational conditions.
Experiments 1 2 3 4 5 6
Pressure (bar) 200 200 200 110 110 110
Temperature (°C) 40 40 40 40 40 40
Time (hours) 2 2 2 2 2 2
Cosolvent concentration 
(v/v), PTN
None Water
(10%)
Ethanol
(10%)
None Water
(10%)
Ethanol
(10%)
Depressurisation rate 
(bars/min)
5 5 5 5 5 5
Table 2. Obtained contact angle for the employed homo- and copolymers and for prepared blends.
Samples Lu 50/50 
Lu/PCL
25/75 
Lu/PCL
PCL 25/75 
Lw/PCL
50/50 
Lw/PCL
75/25 
Lw/PCL
Lw
Contact 
angle ( º)
48.3±0.8 50.1±1.2 55.9±1.3 61.8±1.8 63.6±1.0 66.1±0.9 70.9±1.3 72.5±1.4
Table 3. Fusion enthalpies and relative crystallinities of the prepared blends.
Samples ∆Hf (J/g) Xrel (%)
Lu 109.6 -----
50/50 Lu/PCL 85.7 60.4
25/75 Lu/PCL 80.9 57.0
PCL 72.8 51.3
25/75 Lw/PCL 70.4 49.6
50/50 Lw/PCL 62.1 43.7
75/25 Lw/PCL 57.4 40.4
Lw 116.8 -----
Table 4. Obtained kinetic parameters for kinetic drug release studies: release exponents (n) and kinetic 
constants (k)
Samples k (days-n) n R2
50/50 Lu/PCL 45.22 0.21 0.88
25/75 Lu/PCL 54.93 0.12 0.91
PCL 46.48 0.17 0.94
25/75 Lw/PCL 57.65 0.24 0.96
50/50 Lw/PCL 134.71 0.38 0.96
75/25 Lw/PCL 115.97 0.30 0.99
Table(s)
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